Braden Parker
Corporate Officer/Principal chez ORCHARD THERAPEUTICS PLC
Profil
Braden Parker is currently the Chief Commercial Officer at Orchard Therapeutics Plc.
Previously, he worked as the Vice President & General Manager at PTC Therapeutics, Inc. He completed his undergraduate degree at the University of Notre Dame and holds an MBA from The Leonard N Stern School of Business.
Postes actifs de Braden Parker
Sociétés | Poste | Début |
---|---|---|
ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - |
Anciens postes connus de Braden Parker
Sociétés | Poste | Fin |
---|---|---|
PTC THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Braden Parker
University of Notre Dame | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PTC THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |